An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF‐mutant advanced melanoma treated with first‐line anti‐PD‐1 monotherapies or BRAF/MEK inhibitors in a community‐based oncology setting-Reference-Cited by-同舟云学术

An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF‐mutant advanced melanoma treated with first‐line anti‐PD‐1 monotherapies or BRAF/MEK inhibitors in a community‐based oncology setting

Published:2020-09 Issue:21 Volume:9 Page:7863-7878
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Cowey Charles L.¹²^ORCID,Boyd Marley²^ORCID,Aguilar Kathleen M.²^ORCID,Beeks April²^ORCID,Krepler Clemens³,Scherrer Emilie³

Affiliation:

1. Texas Oncology Baylor Charles A Sammons Cancer Center Dallas TX USA

2. McKesson Life Sciences The Woodlands TX USA

3. Merck & Co., Inc. Kenilworth NJ USA

Funder

Merck Sharp and Dohme

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3312

Reference31 articles.

1. Cancer statistics, 2019

2. National Cancer Institute. Cancer stat facts: melanoma of the skin 2020.https://seer.cancer.gov/statfacts/html/melan.html. Accessed April 9 2020

3. NCCN Guidelines for Cutaneous Melanoma V1.2020. Clinical practice guidelines in oncology: cutaneous melanoma version 1. 2020.https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed December 19 2019.

4. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

5. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NOD2 reduces the chemoresistance of melanoma by inhibiting the TYMS/PLK1 signaling axis;2024-06-14

2. Experimental type 1 diabetes metabolically rejuvenates CD8⁺T cells for improved control of tumor growth through an IGF1-IGF1R axis;2024-04-07

3. Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center’s decade of experience;Frontiers in Oncology;2024-02-21

4. Systemic therapy for Asian patients with advanced BRAF V600‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (B‐CHECK‐RWD study);Cancer Medicine;2023-08-16

5. Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma;Melanoma Research;2022-01-17